HPTN Publications

Metzger DS, Donnell D, Celentano DD, Jackson JB, Shao Y, Aramrattana A, Wei L, Fu L, Ma J, Lucas GM, Chawarski M, Ruan Y, Richardson P, Shin K, Chen RY, Sugarman J, Dye BJ, Rose SM, Beauchamp G, Burns DN; HPTN 058 Protocol Team, Burns DN, HPTN 058 Protocol Team . Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine-Naloxone: HIV Prevention Trials Network 058. JAIDS. 2015, 68: 554-61

Meyer D, Lowensen K, Perrin N, et al, Diane Meyer ,Kelly Lowensen,Nancy Perrin,Ayana Moore,Shruti H. Mehta,Cheryl R. Himmelfarb,Thomas V. Inglesby,Jacky M. Jennings,Alexandra K. Mueller,Jessica N. LaRicci,Woudase Gallo,Adam P. Bocek,Jason E. Farley . An evaluation of the impact of social and structural determinants of health on forgone care during the COVID-19 pandemic in Baltimore, Maryland. PLoS One. 2024

Mgodi NM, Takuva S, Edupuganti S, Karuna S, Andrew P, Lazarus E, Garnett P, Shava E, Mukwekwerere PG, Karg C, Tindale I, Greene E, Luthuli N, Baepanye K, Hural J, Gomez Lorenzo MM, Burns D, Miner MD, Ledgerwood J, Mascola JR, Donnell D, Cohen MS, Corey L, HVTN 703/HPTN 081 Team . A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings. J Acquir Immune Defic Syndr. 2021, 87: 680-687

Miller L, Prieto Merino D, Baisley K, Hayes R. . Hidden heterogeneity: Uncovering patterns of adherence in microbicide trials for HIV prevention.. PLoS One. , 17: e0267011

Miller WC, Hoffman IF, Hanscom BS, Ha TV, Dumchev K, Djoerban Z, Rose SM, Latkin CA, Metzger DS, Lancaster KE, Go VF, Dvoriak S, Mollan KR, Reifeis SA, Piwowar-Manning E, Richardson P, Hudgens MG, Hamilton EL, Sugarman J, Eshleman SH, Susami H, Chu VA, Djauzi S, Kiriazova T, Bui DD, Strathdee SA, Burns DN . A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. Lancet. 2018, 392: 747-759

Mills L, Ndimande-Khoza MN, Velloza J, Atujuna M, Chitukuta M, Hosek S, Chauke H, Musara P, Mangxilana N, Mutero P, Makhale LM, Tauya T, Celum C, Delany-Moretlwe S; HPTN 082 study team. . Motivations for Starting and Stopping PrEP: Experiences of Adolescent Girls and Young Women in the HPTN 082 Trial. AIDS Behav. 2025, 29: 2408-2419

Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, Pinto J, Santos B, Parsons T, Kearney B, Emel L, Herron C, Richardson P, Hudelson SE, Eshleman SH, George K, Fowler MG, Sato P, Mofenson L; HPTN 057 Protocol Team . Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014, 65: 33-41

Mitchell K, Dimitrov D, Hughes J, Moore M, Vittinghoff E, Liu A, Cohen M, Beyrer C, Donnell D, Boily MC . Assessing the use of surveillance data to estimate the impact of prevention interventions on HIV incidence in cluster-randomized controlled trials. Epidemics. 2020, 33